Strados Labs, a cultivate(MD) portfolio company announced a new collaboration with Beth Israel Deaconess Medical Center (BIDMC).
The upcoming study will evaluate the use of Strados Labs’ RESP® Biosensor, an FDA-cleared wearable stethoscope technology, for the early detection of pulmonary edema in critically ill patients on mechanical ventilation (MV). This pilot study is scheduled to begin at the end of February 2025, enrolling 20 patients, with an anticipated duration of 12 months.
This single-center, prospective, observational study will evaluate whether abnormal lung sounds captured by the RESP Biosensor precede currently observed markers and signs of pulmonary edema—a common and life-threatening complication in critically ill patients. The device’s performance will be compared to existing monitoring methods, including daily chest X-rays, intermittent clinical assessments, and fluid intake and output (I&O) tracking.
The study will evaluate continuous lung sound monitoring for the early detection of pulmonary edema and prevention of complications in critically ill ICU patients.